Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Reply to: "Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014".

von Felden J, Mallet V, Pischke S.

J Hepatol. 2019 Oct 1. pii: S0168-8278(19)30532-X. doi: 10.1016/j.jhep.2019.09.004. [Epub ahead of print] No abstract available.

PMID:
31585738
2.

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A.

Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11.

PMID:
31186238
3.

The Impact of Translational Research in Hepatology.

von Felden J, Craig AJ, Villanueva A.

Clin Liver Dis (Hoboken). 2019 Feb 21;13(1):29-33. doi: 10.1002/cld.805. eCollection 2019 Jan. Review. No abstract available.

4.

The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.

von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V.

J Hepatol. 2019 Sep;71(3):465-472. doi: 10.1016/j.jhep.2019.04.022. Epub 2019 May 18.

PMID:
31108159
5.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M.

Aliment Pharmacol Ther. 2019 May;49(10):1323-1333. doi: 10.1111/apt.15245. Epub 2019 Apr 12.

6.

Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study.

Pischke S, Peron JM, von Wulffen M, von Felden J, Höner Zu Siederdissen C, Fournier S, Lütgehetmann M, Iking-Konert C, Bettinger D, Par G, Thimme R, Cantagrel A, Lohse AW, Wedemeyer H, de Man R, Mallet V.

Viruses. 2019 Feb 22;11(2). pii: E186. doi: 10.3390/v11020186.

7.

Detection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical Status.

Landahl J, Bockmann JH, Scheurich C, Ackermann C, Matzat V, Heide J, Nuurei T, D'Antonio G, von Felden J, Sette A, Peine S, Lohse AW, Luetgehetmann M, Marget M, Sidney J, Schulze Zur Wiesch J.

J Infect Dis. 2019 Jan 29;219(4):568-577. doi: 10.1093/infdis/jiy549.

PMID:
30247653
8.

Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma.

von Felden J, Craig AJ, Villanueva A.

Oncoscience. 2018 Aug 22;5(7-8):209-211. doi: 10.18632/oncoscience.446. eCollection 2018 Jul. No abstract available.

9.

High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma.

D'Avola D, Villacorta-Martin C, Martins-Filho SN, Craig A, Labgaa I, von Felden J, Kimaada A, Bonaccorso A, Tabrizian P, Hartmann BM, Sebra R, Schwartz M, Villanueva A.

Sci Rep. 2018 Aug 1;8(1):11570. doi: 10.1038/s41598-018-30047-y.

10.

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.

Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes CV, Woditsch V, Scholten D, Nischalke HD, Janciauskiene S, Mandorfer M, Trauner M, Way MJ, McQuillin A, Reichert MC, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg JM, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Kiefer F, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan MY, Hampe J, Berg T, Trautwein C.

Gut. 2019 Jun;68(6):1099-1107. doi: 10.1136/gutjnl-2018-316228. Epub 2018 Aug 1.

PMID:
30068662
11.

Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis.

Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan MY, Hampe J.

Am J Gastroenterol. 2018 Jul;113(7):1099. doi: 10.1038/s41395-018-0118-4.

PMID:
29895985
12.

Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.

von Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 Jun;47(11):1550-1551. doi: 10.1111/apt.14648. No abstract available.

PMID:
29878436
13.

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.

Labgaa I, Villacorta-Martin C, D'Avola D, Craig AJ, von Felden J, Martins-Filho SN, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A.

Oncogene. 2018 Jul;37(27):3740-3752. doi: 10.1038/s41388-018-0206-3. Epub 2018 Apr 9.

14.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection.

von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh JK, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S.

Aliment Pharmacol Ther. 2018 May;47(9):1288-1295. doi: 10.1111/apt.14592. Epub 2018 Mar 14.

PMID:
29536554
15.

Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.

Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan MY, Hampe J.

Am J Gastroenterol. 2018 Oct;113(10):1475-1483. doi: 10.1038/s41395-018-0041-8. Epub 2018 Mar 13. Erratum in: Am J Gastroenterol. 2018 Jul;113(7):1099.

PMID:
29535416
16.

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.

Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse AW.

J Hepatol. 2018 Apr;68(4):754-763. doi: 10.1016/j.jhep.2017.11.020. Epub 2017 Nov 24.

PMID:
29180000
17.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection.

von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse AW, Riethdorf S, Wege H.

Oncotarget. 2017 Sep 23;8(52):89978-89987. doi: 10.18632/oncotarget.21208. eCollection 2017 Oct 27.

18.

Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals.

Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, de Knegt RJ, Boonstra A.

Gastroenterology. 2018 Feb;154(3):515-517.e3. doi: 10.1053/j.gastro.2017.10.035. Epub 2017 Nov 2.

PMID:
29102620
19.

Molecular profiling of liver cancer heterogeneity.

Craig AJ, von Felden J, Villanueva A.

Discov Med. 2017 Sep;24(131):117-125. Review.

20.

Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome.

von Felden J, Scheurich C, Yamamura J, Brainard DM, Mogalian E, Lohse AW, Schulze Zur Wiesch J.

J Viral Hepat. 2018 Feb;25(2):214-215. doi: 10.1111/jvh.12768. Epub 2017 Aug 30. No abstract available.

PMID:
28783205
21.

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection.

von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse AW, Wege H.

BMC Cancer. 2017 Jan 18;17(1):60. doi: 10.1186/s12885-017-3053-7.

22.

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation.

von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H.

Diagnostics (Basel). 2016 Nov 28;6(4). pii: E44. Review.

23.

MAP-Kinase Activated Protein Kinase 2 Links Endothelial Activation and Monocyte/macrophage Recruitment in Arteriogenesis.

Limbourg A, von Felden J, Jagavelu K, Krishnasamy K, Napp LC, Kapopara PR, Gaestel M, Schieffer B, Bauersachs J, Limbourg FP, Bavendiek U.

PLoS One. 2015 Oct 2;10(10):e0138542. doi: 10.1371/journal.pone.0138542. eCollection 2015.

24.

Mitogen-activated protein kinase-activated protein kinase 2 deficiency reduces insulin sensitivity in high-fat diet-fed mice.

de Boer JF, Dikkers A, Jurdzinski A, von Felden J, Gaestel M, Bavendiek U, Tietge UJ.

PLoS One. 2014 Sep 18;9(9):e106300. doi: 10.1371/journal.pone.0106300. eCollection 2014.

25.

Deficiency of MAPK-activated protein kinase 2 (MK2) prevents adverse remodelling and promotes endothelial healing after arterial injury.

Kapopara PR, von Felden J, Soehnlein O, Wang Y, Napp LC, Sonnenschein K, Wollert KC, Schieffer B, Gaestel M, Bauersachs J, Bavendiek U.

Thromb Haemost. 2014 Dec;112(6):1264-76. doi: 10.1160/TH14-02-0174. Epub 2014 Aug 14.

PMID:
25120198
26.

Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate.

von Felden J, Montani M, Kessebohm K, Stickel F.

Int J Clin Pharmacol Ther. 2013 Mar;51(3):219-23. doi: 10.5414/CP201835.

PMID:
23391366
27.

Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice.

Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert KC, Seegert D, Rose-John S, Tietge UJ, Schieffer B, Grote K.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):281-90. doi: 10.1161/ATVBAHA.111.229435. Epub 2011 Nov 10.

PMID:
22075248

Supplemental Content

Loading ...
Support Center